Guardant Health announced the launch of FPG 360, an on‑site liquid biopsy testing service at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome, leveraging its Guardant360® CDx platform.
The service delivers comprehensive genomic profiling for solid‑tumor patients directly within the hospital, eliminating the need to ship samples abroad and speeding access to precision oncology care for Italian patients.
Italy sees roughly 400,000 new malignant tumor cases each year, with about three deaths per 1,000 people. By providing local, rapid testing, the partnership has the potential to improve early detection and treatment decisions for a large patient population.
The launch is part of Guardant’s strategy to embed its Smart Liquid Biopsy platform in leading academic medical centers, expanding its international footprint and positioning the company to capture a larger share of the growing global liquid biopsy market. Similar collaborations in Barcelona and London reinforce this expansion narrative.
Guardant’s recent financial performance supports the partnership’s significance. In Q3 2025, the company generated $265.2 million in revenue, up 39% year‑over‑year, and achieved a non‑GAAP gross margin of 66%. The company raised its full‑year 2025 revenue guidance to $965–$970 million, reflecting strong demand for its core products and confidence in continued growth.
Helmy Eltoukhy, co‑CEO, said the collaboration “enables broader access for blood‑based cancer profiling and genomic insights, supporting clinicians worldwide in creating more personalized treatment plans.” Professor Antonio Gasbarrini, Scientific Director of Policlinico Gemelli, highlighted the service as a major advancement for Italian cancer patients, who will now benefit from local access to comprehensive genomic profiling.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.